From a global comparison of the genetic landscapes of the murine tumors developing in BRCA2/p53, XRCC4/p53, or Lig4/p53-deficient animals with human MBs and HGGs, respectively, the mouse tumors displayed a significantly lower mutational burden (Fig. 2c, right panel), as reported for mouse models in other tumor entities15. This evidence concerns the gene XRCC4 and neoplasm.